Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EPS (Weighted Average and Diluted) (2019 - 2025)

Historic EPS (Weighted Average and Diluted) for Ptc Therapeutics (PTCT) over the last 10 years, with Q3 2025 value amounting to $0.2.

  • Ptc Therapeutics' EPS (Weighted Average and Diluted) rose 11438.85% to $0.2 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.56, marking a year-over-year increase of 24410.77%. This contributed to the annual value of -$4.73 for FY2024, which is 4351.7% up from last year.
  • Ptc Therapeutics' EPS (Weighted Average and Diluted) amounted to $0.2 in Q3 2025, which was up 11438.85% from -$0.83 recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $10.04 in Q1 2025 and a low of -$2.66 during Q2 2023
  • Its 5-year average for EPS (Weighted Average and Diluted) is -$1.0, with a median of -$1.76 in 2023.
  • As far as peak fluctuations go, Ptc Therapeutics' EPS (Weighted Average and Diluted) plummeted by 2678.57% in 2022, and later skyrocketed by 93666.67% in 2025.
  • Over the past 5 years, Ptc Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$2.02 in 2021, then dropped by 16.83% to -$2.36 in 2022, then grew by 12.71% to -$2.06 in 2023, then skyrocketed by 58.38% to -$0.86 in 2024, then surged by 123.33% to $0.2 in 2025.
  • Its EPS (Weighted Average and Diluted) was $0.2 in Q3 2025, compared to -$0.83 in Q2 2025 and $10.04 in Q1 2025.